- Home
- MIST vs CLLS Comparison
MIST vs CLLS Comparison
Compare MIST & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CLLS
- Stock Information
- Founded
- MIST 2003
- CLLS 1999
- Country
- MIST Canada
- CLLS France
- Employees
- MIST N/A
- CLLS N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- CLLS Health Care
- Exchange
- MIST Nasdaq
- CLLS Nasdaq
- Market Cap
- MIST 132.5M
- CLLS 143.4M
- IPO Year
- MIST N/A
- CLLS 2007
- Fundamental
- Price
- MIST $1.43
- CLLS $2.95
- Analyst Decision
- MIST Strong Buy
- CLLS Buy
- Analyst Count
- MIST 2
- CLLS 1
- Target Price
- MIST $7.50
- CLLS $4.00
- AVG Volume (30 Days)
- MIST 2.9M
- CLLS 310.3K
- Earning Date
- MIST 08-15-2025
- CLLS 08-04-2025
- Dividend Yield
- MIST N/A
- CLLS N/A
- EPS Growth
- MIST N/A
- CLLS N/A
- EPS
- MIST N/A
- CLLS N/A
- Revenue
- MIST N/A
- CLLS $54,747,000.00
- Revenue This Year
- MIST N/A
- CLLS N/A
- Revenue Next Year
- MIST N/A
- CLLS $4.90
- P/E Ratio
- MIST N/A
- CLLS N/A
- Revenue Growth
- MIST N/A
- CLLS 351.26
- 52 Week Low
- MIST $0.63
- CLLS $1.10
- 52 Week High
- MIST $2.75
- CLLS $3.10
- Technical
- Relative Strength Index (RSI)
- MIST 40.51
- CLLS 69.22
- Support Level
- MIST $1.42
- CLLS $2.43
- Resistance Level
- MIST $1.64
- CLLS $3.10
- Average True Range (ATR)
- MIST 0.11
- CLLS 0.27
- MACD
- MIST -0.03
- CLLS 0.08
- Stochastic Oscillator
- MIST 8.95
- CLLS 88.72
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.